Tech Company Financing Transactions
Maxion Therapeutics Funding Round
Maxion Therapeutics, based in Cambridge, secured $16 million in funding from BGF Ventures, LifeArc and Monograph Capital.
Transaction Overview
Company Name
Announced On
2/15/2023
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds for the development of antibody drugs against ion channels and G-protein-coupled receptors (GPCRs) using the proprietary KnotBody platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Moneta Building Babraham Research Campus
Cambridge, CB22 3AT
UK
Cambridge, CB22 3AT
UK
Phone
Undisclosed
Website
Email Address
Overview
Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
John Mccafferty
Browse more venture capital transactions:
Prev: 2/15/2023: MYFLEXBOX venture capital transaction
Next: 2/15/2023: Ironblocks venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC transactions reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs